ArticleJournal of ultrasound2025
Role of platelet rich plasma in management of diabetic peripheral neuropathy: a case-control study.
Article in Journal of ultrasound, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic Peripheral Neuropathy (DPN) is a prevalent complication of diabetes mellitus, resulting in substantial morbidity. This study assesses the effectiveness of platelet-rich plasma (PRP) in managing DPN symptoms and enhancing nerve function.
objectiveTo assess the therapeutic effects of ultrasound-guided perineural injection of PRP on neuropathic pain and nerve conduction parameters in patients with type 2DPN.
methodsThis is a prospective, case-control trial that included 80 participants with type 2 DPN, divided into two groups: Group A (intervention) (n = 40) received ultrasound-guided perineural injections of PRP in conjunction with medical treatment. In contrast, Group B (control) (n = 40) received medical treatment alone. Participants underwent detailed medical history, general and neurological examinations, and laboratory tests. Assessments included nerve conduction studies (NCS), which were conducted at baseline and reassessed after 3 months. The modified Toronto Clinical Neuropathy Score (mTCNS) and Visual Analog Scale (VAS) for pain were measured at baseline and 1- and 3-months post-treatment.
resultsDemographic and baseline clinical characteristics were analogous across groups (p > 0.05). At three months, the intervention group showed a substantial elevation in mNCV for the tibial nerves, from 38.5 ± 5.2 m/s to 45.3 ± 4.8 m/s (p < 0.001), and for the peroneal motor nerves, from 36.2 ± 4.9 m/s to 42.7 ± 5.1 m/s (p < 0.001). The mTCNS scores improved significantly from 12.4 ± 2.1 to 6.3 ± 1.8 (p < 0.001), and VAS scores decreased from 8.2 ± 1.0 to 3.5 ± 1.2 (p < 0.001). Conversely, the control group experienced a deterioration in mTCNS scores, from 12.5 ± 2.0 to 14.1 ± 2.3 (p < 0.01), and an elevation in VAS scores, from 8.1 ± 1.1 to 9.0 ± 0.9 (p < 0.05).
conclusionPRP therapy significantly alleviates symptoms of DPN and enhances nerve function, suggesting its potential as an effective treatment option for diabetic neuropathies.
Indexed as
Identifiers
40624430What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.